Peterlabs Holdings BhdXKLS:0171 47 PB Ratio is 0.84 as of Jun. 26, 2026, which is 7% below its 10-year median of 0.90. GuruFocus rates XKLS:0171 with a GF Score™ of 47/100 and a GF Value™ of RM0.20 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Peterlabs Holdings Bhd ranks better than 81.34% on this metric.
The historical rank and industry rank for Peterlabs Holdings Bhd's PB Ratio or its related term are showing as below:
XKLS:0171'
s PB Ratio Range Over the Past 10 Years
Min: 0.57 Med: 0.9 Max: 1.81
Current: 0.84
During the past 13 years, Peterlabs Holdings Bhd's highest PB Ratio was 1.81. The lowest was 0.57. And the median was 0.90.
XKLS:0171's PB Ratio is ranked better than 81.34% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs XKLS:0171: 0.84
During the past 12 months, Peterlabs Holdings Bhd's average Book Value Per Share Growth Rate was -1.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Peterlabs Holdings Bhd was 15.20% per year. The lowest was 3.40% per year. And the median was 6.00% per year.
Back to Basics: PB Ratio
Peterlabs Holdings Bhd (XKLS:0171) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Peterlabs Holdings Bhd's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peterlabs Holdings Bhd PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peterlabs Holdings Bhd's PB Ratio distribution charts can be found below:
* The bar in red indicates where Peterlabs Holdings Bhd's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Peterlabs Holdings Bhd (XKLS:0171) has a PB Ratio of 0.84 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Peterlabs Holdings Bhd and its competitors. This is near median its historical median of 0.90. Over the past decade, Peterlabs Holdings Bhd's PB Ratio has ranged from 0.57 to 1.81. According to the industry distribution chart, Peterlabs Holdings Bhd ranks #172 out of 922 companies in the Drug Manufacturers industry, placing it in the top 18.7%.
Is Peterlabs Holdings Bhd's PB Ratio too high?
Peterlabs Holdings Bhd's current PB Ratio of 0.84 is near median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 1.81. The Drug Manufacturers industry median PB Ratio is 1.83. Peterlabs Holdings Bhd's value of 0.84 is 54% below this industry median. Based on the distribution chart, Peterlabs Holdings Bhd ranks #172 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Peterlabs Holdings Bhd has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Peterlabs Holdings Bhd ranks #172 out of 922 companies for PB Ratio. This places Peterlabs Holdings Bhd in the top 19% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.83. Peterlabs Holdings Bhd's value of 0.84 is 54% below this benchmark. Historically, Peterlabs Holdings Bhd's own PB Ratio has ranged from 0.57 to 1.81 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 1.83, Peterlabs Holdings Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Peterlabs Holdings Bhd's current PB Ratio of 0.84 is 54% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Peterlabs Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current PB Ratio is 0.84, which is near median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd (XKLS:0171) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.20, compared to a current price of RM0.24 — trading 17.5% above its estimated fair value. The current PB Ratio is 0.84, which is near median its 10-year median of 0.90 and 54% below the Drug Manufacturers industry median of 1.83. Peterlabs Holdings Bhd's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current PB Ratio is 0.84 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peterlabs Holdings Bhd (XKLS:0171) Overvalued in 2026?
Based on GuruFocus' analysis, Peterlabs Holdings Bhd stock appears to be overvalued.
The current stock price of RM0.24 is trading 17.5% above its estimated GF Value™ of RM0.20.
GuruFocus considers Peterlabs Holdings Bhd to be Modestly Overvalued.
Key valuation signals for XKLS:0171:
PB Ratio: 0.84 (near median its 10-year median of 0.90)
GF Value™: RM0.20 vs. price of RM0.24 (17.5% above fair value)
Industry Position: 54% below the Drug Manufacturers median (#172 of 922)
No single metric tells the full story. See the XKLS:0171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
47GF Score
Get the complete analysis for XKLS:0171
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
